{"id":"W2599986771","doi":"10.1182/blood.v108.11.2430.2430","title":"Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Tolerability; Medicine; Dosing; Proteasome inhibitor; Internal medicine; Macroglobulinemia; Adverse effect; Phases of clinical research; Multiple myeloma; Pharmacokinetics; Pharmacology; Clinical trial; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003650041,0.001511018,0.001855042,0.0003761135,0.0005780364,0.0007159659,0.000964453,0.0009522774,0.002404844],"category_scores_gemma":[0.001012302,0.0004714504,0.001092496,0.0005284827,0.00083147,0.000796949,0.0004039638,0.003370596,0.0005996099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001182766,"about_ca_system_score_gemma":0.001535651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007476599,"about_ca_topic_score_gemma":0.001332676,"domain_scores_codex":[0.9990025,0.0004935135,0.00005897752,0.0001584745,0.00009084108,0.0001956976],"domain_scores_gemma":[0.998728,0.0001753564,0.0003261873,0.0001622328,0.0001041294,0.0005039894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.469322,0.1290522,0.02061614,0.0009099842,0.001768873,0.0005060495,0.0007229313,0.004077591,0.2046812,0.0005294125,0.008404738,0.1594089],"study_design_scores_gemma":[0.2223211,0.739712,0.02110751,0.00002500804,0.0003759975,0.000442252,0.00005717206,0.000699207,0.01173563,0.0001382317,0.00335523,0.00003062027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894577,0.002168006,0.001487006,0.0003619418,0.0001012371,0.00399753,0.001033797,0.00012584,0.001266985],"genre_scores_gemma":[0.9827645,0.001124242,0.004092714,0.000826924,0.0001941412,0.005208155,0.004054698,0.00004435787,0.001690162],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003650041,"threshold_uncertainty_score":0.0193035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0262257796735674,"score_gpt":0.3154442726249826,"score_spread":0.2892184929514152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}